{
    "eid": "2-s2.0-85141590781",
    "title": "Phosphoproteomic Analysis Defines BABAM1 as mTORC2 Downstream Effector Promoting DNA Damage Response in Glioblastoma Cells",
    "cover-date": "2022-12-02",
    "subject-areas": [
        {
            "@_fa": "true",
            "$": "Chemistry (all)",
            "@code": "1600",
            "@abbrev": "CHEM"
        },
        {
            "@_fa": "true",
            "$": "Biochemistry",
            "@code": "1303",
            "@abbrev": "BIOC"
        }
    ],
    "keywords": [
        "BABAM1",
        "DNA damage response",
        "glioblastoma",
        "mTORC2",
        "phosphoproteomics"
    ],
    "authors": [
        "Nuttiya Kalpongnukul",
        "Rungnapa Bootsri",
        "Piriya Wongkongkathep",
        "Pornchai Kaewsapsak",
        "Chaiyaboot Ariyachet",
        "Trairak Pisitkun",
        "Naphat Chantaravisoot"
    ],
    "citedby-count": 2,
    "ref-count": 33,
    "ref-list": [
        "Symptom management of brain tumor patients",
        "MTOR signaling in glioblastoma: Lessons learned from bench to bedside",
        "MTORC2 in the center of cancer metabolic reprogramming",
        "MTOR signaling at a glance",
        "PP242 counteracts glioblastoma cell proliferation, migration, invasiveness and stemness properties by inhibiting mTORC2/AKT",
        "MTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma",
        "The mTOR pathway: Implications for DNA replication",
        "Phosphoproteomics in cancer",
        "Impact of Phosphoproteomics in the Era of Precision Medicine for Prostate Cancer",
        "AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity",
        "MERIT40 facilitates BRCA1 localization and DNA damage repair",
        "?H2AX: A sensitive molecular marker of DNA damage and repair",
        "MTOR signaling pathway and mTOR inhibitors in cancer: Progress and challenges",
        "The mTOR-S6K pathway links growth signalling to DNA damage response by targeting RNF168",
        "Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival",
        "Regulation of mTORC2 signaling",
        "Significance of filamin A in mTORC2 function in glioblastoma",
        "MTOR complex 2 signaling and functions",
        "Evaluation of Akt and RICTOR Expression Levels in Astrocytomas of All Grades",
        "Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome",
        "Single-cell phosphoproteomics resolves adaptive signaling dynamics and informs targeted combination therapy in glioblastoma",
        "Tumor Drug Concentration and Phosphoproteomic Profiles after Two Weeks of Treatment with Sunitinib in Patients with Newly Diagnosed GlioblastomaGBM: Tumor Sunitinib Concentrations and Phosphoproteomics",
        "Revisiting CDK inhibitors for treatment of glioblastoma multiforme",
        "Ubiquitin-binding protein RAP80 mediates BRCA1-dependent DNA damage response",
        "MERIT40-dependent recruitment of tankyrase to damaged DNA and its implication for cell sensitivity to DNA-damaging anticancer drugs",
        "MERIT40 is an Akt substrate that promotes resolution of DNA damage induced by chemotherapy",
        "Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma",
        "Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair",
        "Akt promotes post-irradiation survival of human tumor cells through initiation, progression, and termination of DNA-PKcs-dependent DNA double-strand break repair",
        "TORC2 signaling pathway guarantees genome stability in the face of DNA strand breaks",
        "Targeting the DNA damage response in cancer",
        "BRCA1 Protein Expression Predicts Survival in Glioblastoma Patients from an NRG Oncology RTOG Cohort",
        "BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening"
    ],
    "affiliation": [
        {
            "affiliation-city": "Bangkok",
            "@id": "60002620",
            "affilname": "Faculty of Medicine, Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60002620",
            "affiliation-country": "Thailand"
        },
        {
            "affiliation-city": "Bangkok",
            "@id": "60028190",
            "affilname": "Chulalongkorn University",
            "@href": "https://api.elsevier.com/content/affiliation/affiliation_id/60028190",
            "affiliation-country": "Thailand"
        }
    ],
    "funding": [
        "OHEC",
        "IPST",
        "Chulalongkorn University",
        "Thailand Research Fund",
        "National Research Council of Thailand",
        "Faculty of Medicine, Chulalongkorn University"
    ]
}